Elucid raises $55M Series D to advance its AI software for cardiovascular CT analysis.
Key Details
- 1Boston-based Elucid closed an oversubscribed $55 million Series D round.
- 2Funding included participation from a major, unnamed, publicly traded medtech firm.
- 3Elucid has raised over $185 million to date.
- 4Its AI software assists physicians in analyzing CT scans for signs of cardiovascular disease.
- 5The funding will support clinical platform expansion, FFR-CT development (under FDA review), and continued R&D.
- 6Elucid now has four large, publicly traded strategic investors.
Why It Matters
Significant investment underscores the continued momentum and competition in AI-driven cardiovascular imaging. The funding supports further product development and regulatory progress, potentially impacting diagnostic accuracy and patient care in radiology.
Source
Radiology Business
Related News
•Radiology Business
Vara's AI Gains World's First Approval for Radiologist-Free Mammogram Triage
Vara has secured the world's first regulatory approval for an AI tool that autonomously classifies certain mammograms as normal, bypassing radiologist review.
•AuntMinnie
AI Tool Cuts Radiologist Reporting Time for Chest CTs by 15%
Real-world study finds commercial AI for pulmonary nodule detection reduces chest CT reporting times by nearly 15%.
•Radiology Business
AI Tool Shortens Pulmonary Nodule Assessment in Chest CT
Commercial AI software reduces reporting times for pulmonary nodule assessment in chest CT by up to 25%.